Aggregated adverse-events outcomes in oncology phase III reports: A systematic review.
Identifieur interne : 002394 ( Main/Exploration ); précédent : 002393; suivant : 002395Aggregated adverse-events outcomes in oncology phase III reports: A systematic review.
Auteurs : Denis Maillet [France] ; Hui K. Gan [Australie] ; Jean-Yves Blay [Belgique] ; Benoit You [France] ; Julien Péron [France]Source :
- European journal of cancer (Oxford, England : 1990) [ 1879-0852 ] ; 2016.
Descripteurs français
- KwdFr :
- Analyse multivariée, Antinéoplasiques (effets indésirables), Effets secondaires indésirables des médicaments (diagnostic), Effets secondaires indésirables des médicaments (étiologie), Essais contrôlés randomisés comme sujet (), Essais contrôlés randomisés comme sujet (normes), Humains, Oncologie médicale (), Oncologie médicale (normes), Plan de recherche (normes), Résultat thérapeutique, Systèmes de signalement des effets indésirables des médicaments (normes), Tumeurs (traitement médicamenteux).
- MESH :
- diagnostic : Effets secondaires indésirables des médicaments.
- effets indésirables : Antinéoplasiques.
- normes : Essais contrôlés randomisés comme sujet, Oncologie médicale, Plan de recherche, Systèmes de signalement des effets indésirables des médicaments.
- traitement médicamenteux : Tumeurs.
- étiologie : Effets secondaires indésirables des médicaments.
- Analyse multivariée, Essais contrôlés randomisés comme sujet, Humains, Oncologie médicale, Résultat thérapeutique.
English descriptors
- KwdEn :
- Adverse Drug Reaction Reporting Systems (standards), Antineoplastic Agents (adverse effects), Drug-Related Side Effects and Adverse Reactions (diagnosis), Drug-Related Side Effects and Adverse Reactions (etiology), Humans, Medical Oncology (methods), Medical Oncology (standards), Multivariate Analysis, Neoplasms (drug therapy), Randomized Controlled Trials as Topic (methods), Randomized Controlled Trials as Topic (standards), Research Design (standards), Treatment Outcome.
- MESH :
- chemical , adverse effects : Antineoplastic Agents.
- diagnosis : Drug-Related Side Effects and Adverse Reactions.
- drug therapy : Neoplasms.
- etiology : Drug-Related Side Effects and Adverse Reactions.
- methods : Medical Oncology, Randomized Controlled Trials as Topic.
- standards : Adverse Drug Reaction Reporting Systems, Medical Oncology, Randomized Controlled Trials as Topic, Research Design.
- Humans, Multivariate Analysis, Treatment Outcome.
Abstract
Randomised controlled trials (RCTs) represent a major source of information on treatment-related adverse events (AEs). In this study, we reviewed the use and the reporting methods of aggregated-AEs (A-AEs) outcomes in RCTs reports published in oncology and compared that to the expectations of European Organisation for Research and Treatment of Cancer (EORTC) membership.
DOI: 10.1016/j.ejca.2015.08.025
PubMed: 26630531
Affiliations:
- Australie, Belgique, France
- Auvergne-Rhône-Alpes, Rhône-Alpes, Région de Bruxelles-Capitale, Victoria (État)
- Bruxelles, Lyon, Melbourne, Pierre-Bénite, Villeurbanne
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002519
- to stream PubMed, to step Curation: 002451
- to stream PubMed, to step Checkpoint: 002451
- to stream Ncbi, to step Merge: 002E17
- to stream Ncbi, to step Curation: 002E17
- to stream Ncbi, to step Checkpoint: 002E17
- to stream Main, to step Merge: 002393
- to stream Main, to step Curation: 002394
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Aggregated adverse-events outcomes in oncology phase III reports: A systematic review.</title><author><name sortKey="Maillet, Denis" sort="Maillet, Denis" uniqKey="Maillet D" first="Denis" last="Maillet">Denis Maillet</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology Department, Centre Hospitalier Lyon-Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, F-69310, Pierre-Bénite, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Medical Oncology Department, Centre Hospitalier Lyon-Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, F-69310, Pierre-Bénite</wicri:regionArea><wicri:noRegion>69310, Pierre-Bénite</wicri:noRegion><wicri:noRegion>69310, Pierre-Bénite</wicri:noRegion></affiliation></author><author><name sortKey="Gan, Hui K" sort="Gan, Hui K" uniqKey="Gan H" first="Hui K" last="Gan">Hui K. Gan</name><affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Unit, Olivia Newton-John Cancer and Wellness Centre, Austin Hospital, Melbourne, Victoria, Australia; School of Cancer Medicine, La Trobe University, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Medical Oncology Unit, Olivia Newton-John Cancer and Wellness Centre, Austin Hospital, Melbourne, Victoria, Australia; School of Cancer Medicine, La Trobe University, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Blay, Jean Yves" sort="Blay, Jean Yves" uniqKey="Blay J" first="Jean-Yves" last="Blay">Jean-Yves Blay</name><affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Centre Léon Bérard, Lyon, France; EORTC, 83 Avenue Mounier, Bruxelles, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Medical Oncology Department, Centre Léon Bérard, Lyon, France; EORTC, 83 Avenue Mounier, Bruxelles</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="You, Benoit" sort="You, Benoit" uniqKey="You B" first="Benoit" last="You">Benoit You</name><affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Centre Hospitalier Lyon-Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, F-69310, Pierre-Bénite, France; EMR UCBL/HCL 3738, Faculté de Médecine Lyon-Sud, F-69600, Oullins, France; Université de Lyon, F-69622, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Medical Oncology Department, Centre Hospitalier Lyon-Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, F-69310, Pierre-Bénite, France; EMR UCBL/HCL 3738, Faculté de Médecine Lyon-Sud, F-69600, Oullins, France; Université de Lyon, F-69622, Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Peron, Julien" sort="Peron, Julien" uniqKey="Peron J" first="Julien" last="Péron">Julien Péron</name><affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Centre Hospitalier Lyon-Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, F-69310, Pierre-Bénite, France; Hospices Civils de Lyon, Biostatistics Unit, F-69003, Lyon, France; CNRS UMR 5558, Biometry and Evolutionary Biology Laboratory, Health and Biostatistics Team, Villeurbanne, France. Electronic address: julien.peron@chu-lyon.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Medical Oncology Department, Centre Hospitalier Lyon-Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, F-69310, Pierre-Bénite, France; Hospices Civils de Lyon, Biostatistics Unit, F-69003, Lyon, France; CNRS UMR 5558, Biometry and Evolutionary Biology Laboratory, Health and Biostatistics Team, Villeurbanne</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Villeurbanne</settlement><settlement type="city" wicri:auto="agglo">Lyon</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26630531</idno><idno type="pmid">26630531</idno><idno type="doi">10.1016/j.ejca.2015.08.025</idno><idno type="wicri:Area/PubMed/Corpus">002519</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002519</idno><idno type="wicri:Area/PubMed/Curation">002451</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002451</idno><idno type="wicri:Area/PubMed/Checkpoint">002451</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002451</idno><idno type="wicri:Area/Ncbi/Merge">002E17</idno><idno type="wicri:Area/Ncbi/Curation">002E17</idno><idno type="wicri:Area/Ncbi/Checkpoint">002E17</idno><idno type="wicri:Area/Main/Merge">002393</idno><idno type="wicri:Area/Main/Curation">002394</idno><idno type="wicri:Area/Main/Exploration">002394</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Aggregated adverse-events outcomes in oncology phase III reports: A systematic review.</title><author><name sortKey="Maillet, Denis" sort="Maillet, Denis" uniqKey="Maillet D" first="Denis" last="Maillet">Denis Maillet</name><affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Centre Hospitalier Lyon-Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, F-69310, Pierre-Bénite, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Medical Oncology Department, Centre Hospitalier Lyon-Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, F-69310, Pierre-Bénite</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Pierre-Bénite</settlement></placeName></affiliation></author><author><name sortKey="Gan, Hui K" sort="Gan, Hui K" uniqKey="Gan H" first="Hui K" last="Gan">Hui K. Gan</name><affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Unit, Olivia Newton-John Cancer and Wellness Centre, Austin Hospital, Melbourne, Victoria, Australia; School of Cancer Medicine, La Trobe University, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Medical Oncology Unit, Olivia Newton-John Cancer and Wellness Centre, Austin Hospital, Melbourne, Victoria, Australia; School of Cancer Medicine, La Trobe University, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Blay, Jean Yves" sort="Blay, Jean Yves" uniqKey="Blay J" first="Jean-Yves" last="Blay">Jean-Yves Blay</name><affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Centre Léon Bérard, Lyon, France; EORTC, 83 Avenue Mounier, Bruxelles, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Medical Oncology Department, Centre Léon Bérard, Lyon, France; EORTC, 83 Avenue Mounier, Bruxelles</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="You, Benoit" sort="You, Benoit" uniqKey="You B" first="Benoit" last="You">Benoit You</name><affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Centre Hospitalier Lyon-Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, F-69310, Pierre-Bénite, France; EMR UCBL/HCL 3738, Faculté de Médecine Lyon-Sud, F-69600, Oullins, France; Université de Lyon, F-69622, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Medical Oncology Department, Centre Hospitalier Lyon-Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, F-69310, Pierre-Bénite, France; EMR UCBL/HCL 3738, Faculté de Médecine Lyon-Sud, F-69600, Oullins, France; Université de Lyon, F-69622, Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Peron, Julien" sort="Peron, Julien" uniqKey="Peron J" first="Julien" last="Péron">Julien Péron</name><affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Centre Hospitalier Lyon-Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, F-69310, Pierre-Bénite, France; Hospices Civils de Lyon, Biostatistics Unit, F-69003, Lyon, France; CNRS UMR 5558, Biometry and Evolutionary Biology Laboratory, Health and Biostatistics Team, Villeurbanne, France. Electronic address: julien.peron@chu-lyon.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Medical Oncology Department, Centre Hospitalier Lyon-Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, F-69310, Pierre-Bénite, France; Hospices Civils de Lyon, Biostatistics Unit, F-69003, Lyon, France; CNRS UMR 5558, Biometry and Evolutionary Biology Laboratory, Health and Biostatistics Team, Villeurbanne</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Villeurbanne</settlement><settlement type="city" wicri:auto="agglo">Lyon</settlement></placeName></affiliation></author></analytic><series><title level="j">European journal of cancer (Oxford, England : 1990)</title><idno type="eISSN">1879-0852</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adverse Drug Reaction Reporting Systems (standards)</term><term>Antineoplastic Agents (adverse effects)</term><term>Drug-Related Side Effects and Adverse Reactions (diagnosis)</term><term>Drug-Related Side Effects and Adverse Reactions (etiology)</term><term>Humans</term><term>Medical Oncology (methods)</term><term>Medical Oncology (standards)</term><term>Multivariate Analysis</term><term>Neoplasms (drug therapy)</term><term>Randomized Controlled Trials as Topic (methods)</term><term>Randomized Controlled Trials as Topic (standards)</term><term>Research Design (standards)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Analyse multivariée</term><term>Antinéoplasiques (effets indésirables)</term><term>Effets secondaires indésirables des médicaments (diagnostic)</term><term>Effets secondaires indésirables des médicaments (étiologie)</term><term>Essais contrôlés randomisés comme sujet ()</term><term>Essais contrôlés randomisés comme sujet (normes)</term><term>Humains</term><term>Oncologie médicale ()</term><term>Oncologie médicale (normes)</term><term>Plan de recherche (normes)</term><term>Résultat thérapeutique</term><term>Systèmes de signalement des effets indésirables des médicaments (normes)</term><term>Tumeurs (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antinéoplasiques</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Drug-Related Side Effects and Adverse Reactions</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Medical Oncology</term><term>Randomized Controlled Trials as Topic</term></keywords><keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Essais contrôlés randomisés comme sujet</term><term>Oncologie médicale</term><term>Plan de recherche</term><term>Systèmes de signalement des effets indésirables des médicaments</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Adverse Drug Reaction Reporting Systems</term><term>Medical Oncology</term><term>Randomized Controlled Trials as Topic</term><term>Research Design</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Multivariate Analysis</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Analyse multivariée</term><term>Essais contrôlés randomisés comme sujet</term><term>Humains</term><term>Oncologie médicale</term><term>Résultat thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Randomised controlled trials (RCTs) represent a major source of information on treatment-related adverse events (AEs). In this study, we reviewed the use and the reporting methods of aggregated-AEs (A-AEs) outcomes in RCTs reports published in oncology and compared that to the expectations of European Organisation for Research and Treatment of Cancer (EORTC) membership.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Belgique</li><li>France</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Rhône-Alpes</li><li>Région de Bruxelles-Capitale</li><li>Victoria (État)</li></region><settlement><li>Bruxelles</li><li>Lyon</li><li>Melbourne</li><li>Pierre-Bénite</li><li>Villeurbanne</li></settlement></list><tree><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Maillet, Denis" sort="Maillet, Denis" uniqKey="Maillet D" first="Denis" last="Maillet">Denis Maillet</name></region><name sortKey="Peron, Julien" sort="Peron, Julien" uniqKey="Peron J" first="Julien" last="Péron">Julien Péron</name><name sortKey="You, Benoit" sort="You, Benoit" uniqKey="You B" first="Benoit" last="You">Benoit You</name></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Gan, Hui K" sort="Gan, Hui K" uniqKey="Gan H" first="Hui K" last="Gan">Hui K. Gan</name></region></country><country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Blay, Jean Yves" sort="Blay, Jean Yves" uniqKey="Blay J" first="Jean-Yves" last="Blay">Jean-Yves Blay</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002394 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002394 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26630531
|texte= Aggregated adverse-events outcomes in oncology phase III reports: A systematic review.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26630531" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |